BioSpace News Archive

POXEL SA today announced its calendar for the publication of financial information for 2023.

FzioMed, Inc., a global leading surgical biomaterials company focused on spine/orthopedic, peritoneal and gynecological surgery, announced the appointment of industry veteran Paul Mraz as its new President and CEO and member of the Board of Directors.

Rakuten Medical, Inc. will present on how the company has been advancing its technology, and how it plans to continue doing so, in order to reach more patients around the world at the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12, 2023.

Metagenomi today announced that Brian C. Thomas, Ph.D., Chief Executive Officer and Founder of Metagenomi, will present a company overview at 11:00 a.m. PT on Monday, January 9, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.

Stuart Therapeutics, Inc., announces that it has entered into a license agreement with AJU Pharm Co. Ltd., for Stuart’s clinical stage drug candidate ST-100.

G1 Therapeutics, Inc. announced that on January 11, 2023, at 1:30 PM PST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 41st Annual J.P. Morgan Healthcare Conference.

Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Tuesday, January 10, 2023.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on January 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 2 individuals hired by Acutus in December 2022.

Minerva Surgical, Inc. announced that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 9:45 a.m. Pacific Time.

MaxCyte, Inc. announced the signing of a strategic platform license with Catamaran Bio, Inc., a biotechnology company developing novel, off the-shelf chimeric antigen receptor -NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors.